Two Sigma Advisers LP Sells 20,100 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Two Sigma Advisers LP decreased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 2.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 881,783 shares of the medical device company's stock after selling 20,100 shares during the period. Two Sigma Advisers LP owned 1.34% of Tandem Diabetes Care worth $31,762,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Two Sigma Investments LP boosted its holdings in Tandem Diabetes Care by 4.4% in the fourth quarter. Two Sigma Investments LP now owns 861,188 shares of the medical device company's stock worth $31,020,000 after acquiring an additional 36,475 shares in the last quarter. State of Wyoming boosted its holdings in Tandem Diabetes Care by 95.9% in the fourth quarter. State of Wyoming now owns 2,996 shares of the medical device company's stock worth $108,000 after acquiring an additional 1,467 shares in the last quarter. Shell Asset Management Co. boosted its holdings in Tandem Diabetes Care by 16.9% in the fourth quarter. Shell Asset Management Co. now owns 26,281 shares of the medical device company's stock worth $947,000 after acquiring an additional 3,803 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new position in Tandem Diabetes Care in the fourth quarter worth approximately $332,000. Finally, Silvercrest Asset Management Group LLC boosted its holdings in Tandem Diabetes Care by 29.2% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 346,565 shares of the medical device company's stock worth $12,483,000 after acquiring an additional 78,347 shares in the last quarter.

Insider Transactions at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the acquisition, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.90% of the company's stock.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock traded up $0.08 during trading on Friday, hitting $20.72. The stock had a trading volume of 945,052 shares, compared to its average volume of 1,487,297. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The stock's 50 day moving average is $19.40 and its two-hundred day moving average is $27.46. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -10.74 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm had revenue of $234.42 million during the quarter, compared to analysts' expectations of $220.19 million. During the same period in the prior year, the business earned ($0.65) earnings per share. The business's quarterly revenue was up 22.3% compared to the same quarter last year. As a group, analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TNDM shares. Mizuho started coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective for the company. Canaccord Genuity Group increased their price objective on Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Barclays lowered their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Citigroup increased their price objective on Tandem Diabetes Care from $20.00 to $24.00 and gave the stock a "neutral" rating in a research note on Thursday. Finally, Piper Sandler lowered their price objective on Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and a consensus target price of $37.47.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.